Abstract Library

#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors

Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Olivia H

Authors: Hentic O, Cros J, Rebours V, Zappa M, Muller N,

Keywords: dedifferentiation, new biopsy,

#1880 Dedifferentiation of Metastatic Pancreatic Neuroendocrine Neoplasms

Introduction: Neuroendocrine neoplasms (NENs) exhibit significant differences in growth behavior. Their metastatic disease may dedifferentiate presenting a more aggressive biological behavior

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alexandraki K, Boutzios G, Kaltsatou M, Nikolopoulos G, Moschouris P,

Keywords: dedifferentiation,

#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?

Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kamp K

Authors: Kamp K, Adrichem van R, Vandamme T, Peeters M, Feelders R,

Keywords: GEP-NET, CgA, prognosis,